American Society of Nephrology (ASN)

Kidney Health Initiative Urges Investigators to Include People with Kidney Diseases in Clinical Trials for Coronavirus 2019 (COVID-19) Therapies

9-Jun-2020 1:45 PM EDT, by American Society of Nephrology (ASN)

 

Highlights:

  • People with kidney diseases are often excluded from clinical trials because of the complexity and high morbidity of kidney disease.
  • COVID-19 puts people with kidney diseases at a two to sixteen-fold increased risk of severe symptoms.
  • All investigators should include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19.

  

Newswise — Washington, DC (June 9, 2020) — Clinical trials often exclude people with kidney diseases. This practice could have significant consequences, if continued, during the Coronavirus – 2019 (COVID-19) pandemic and for the 37 million Americans with kidney diseases who are at high risk of severe disease.

Preliminary studies indicate that people with kidney diseases demonstrate an increased risk (two- to sixteen-fold) for developing severe COVID-19 symptoms. These data support US statistics that show acute kidney injury occurs in up to 5% of hospitalized COVID-19 patients and 50-90% of patients in the intensive care unit. An effective response to the COVID-19 pandemic should include people with kidney diseases.

The KHI Board of Directors considered a variety of issues impacting drug and device development in the kidney community during the COVID-19 pandemic and identified inclusion of people with kidney diseases in clinical trials for COVID-19 therapies as central to improving care. The recent statement, written by members of the Board of Directors is titled “Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials”.

“Given their increased risk, people with kidney diseases deserve to be prioritized in the development of novel therapies for COVID-19,” said Raymond C. Harris, MD, FASN, Co-Chair of KHI, “KHI urges sponsors and investigators to come alongside the US Food and Drug Administration (FDA) and the patient community to expand their research into this vulnerable population.”

The FDA encourages enrollment practices that lead to clinical trials better reflecting the population most likely to use and benefit from the therapy being studied. This can be achieved through novel trial designs or broadening eligibility criteria, when appropriate, to increase enrollment of underrepresented populations. A recent guidance from the FDA titled “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention” explicitly encouraged sponsors to include people with kidney diseases in their COVID-19 trials.   

As the largest consortia in the kidney community and a public-private partnership between the American Society of Nephrology and the FDA, KHI urges all investigators to include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19. This population demonstrates increased risk of exposure, infection, and severe morbidity, and inclusion of people with kidney diseases in trials would benefit all aspects of health care.

Individuals who are interested in learning more about KHI, should contact Melissa West, Acting Vice President for Research, Discovery and Innovation, at mwest@asn-online.org

The Kidney Health Initiative (KHI) is a key part of the newly created ASN Alliance for Kidney Health. KHI is uniquely positioned to realize ASN’s vision of a world without kidney diseases. As a public-private and collaborative partnership with the FDA and more than 100 organizations and companies, KHI catalyzes innovation and the development of safe and effective patient-centered therapies for people living with kidney diseases. Learn more at www.kidneyhealthinitiative.org.

 

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.

 

# # #

 

 




Filters close

Showing results

110 of 2450
Newswise: Newer variant of COVID-19–causing virus dominates global infections
Released: 2-Jul-2020 12:10 PM EDT
Newer variant of COVID-19–causing virus dominates global infections
Los Alamos National Laboratory

Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture.

Newswise: From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
Released: 2-Jul-2020 12:05 PM EDT
From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
La Jolla Institute for Immunology

Two variants of the novel coronavirus (SARS-CoV-2), called G614 and D614, were circulating in mid-March. A new study shows that the G version of the virus has come to dominate cases around the world. They report that this mutation does not make the virus more deadly, but it does help the virus copy itself, resulting in a higher viral load, or "titer," in patients.

Released: 2-Jul-2020 11:50 AM EDT
New Study Explains Potential Causes for “Happy Hypoxia” Condition in COVID-19 Patients
Loyola Medicine

A new research study provides possible explanations for COVID-19 patients who present with extremely low, otherwise life-threatening levels of oxygen, but no signs of dyspnea (difficulty breathing). This new understanding of the condition, known as silent hypoxemia or “happy hypoxia,” could prevent unnecessary intubation and ventilation in patients during the current and expected second wave of coronavirus.

Released: 2-Jul-2020 10:15 AM EDT
Stemming the Spread of Misinformation on Social Media
Association for Psychological Science

New research reported in the journal Psychological Science finds that priming people to think about accuracy could make them more discerning in what they subsequently share on social media.

29-Jun-2020 9:00 AM EDT
Coronavirus damages the endocrine system
Endocrine Society

People with endocrine disorders may see their condition worsen as a result of COVID-19, according to a new review published in the Journal of the Endocrine Society.

Released: 2-Jul-2020 8:50 AM EDT
Learn from the pandemic to prevent environmental catastrophe, scientists argue
University of Cambridge

• COVID-19 is comparable to climate and extinction emergencies, say scientists from the UK and US – all share features such as lagged impacts, feedback loops, and complex dynamics. • Delayed action in the pandemic cost lives and economic growth, just as it will with environmental crises – but on a scale “too grave to contemplate”.

Released: 1-Jul-2020 5:30 PM EDT
COVID-19 seed grants awarded to 7 ISU research projects
Iowa State University

Iowa State's COVID-19 Research Seed Grant program will support the initial stages of high-risk/high-reward projects that address the COVID-19 crisis.

Released: 1-Jul-2020 4:30 PM EDT
National Survey on COVID-19 Pandemic Shows Significant Mental Health Impact
Beth Israel Deaconess Medical Center

The findings of a nationwide survey assessing the effects of the COVID-19 pandemic on the emotional wellbeing of U.S. adults show 90 percent of survey respondents reported experiencing emotional distress related to the pandemic.

Released: 1-Jul-2020 2:40 PM EDT
Surveys Reveal Significant Shifts in Consumer Behavior During Pandemic
Rensselaer Polytechnic Institute (RPI)

The COVID-19 pandemic has significantly altered how people shop, how much they buy, the trips they take outside their homes, and the number of tele-activities — like work, medicine, and education — that have become commonplace. These changes were rapid and have tremendously impacted the economy, supply chains, and the environment. Two sets of surveys were conducted by researchers at Rensselaer Polytechnic Institute in an effort to quantify and understand these unprecedented shifts — and evaluate the likelihood they may last after the pandemic has ended.


Showing results

110 of 2450

close
0.96679